Open AccessPharmacological cancer treatment and venous thromboembolism risk
Author(s) -
Andrés J. Muñoz Martín,
Sara Ramírez,
L. Ortega Morán,
Magdalena Ruiz Zamorano,
María Carmen Viñuela Benéitez,
Inmaculada Aparicio Salcedo,
Ignacio Escobar,
José Manuel Soria
Publication year - 2020
Publication title -
european heart journal supplements
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.389
H-Index - 36
eISSN - 1554-2815
pISSN - 1520-765X
DOI - 10.1093/eurheartj/suaa004
Subject(s) - medicine , immunotherapy , cancer , venous thromboembolism , chemotherapy , oncology , risk factor , intensive care medicine , thrombosis
Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. Chemotherapy has been identified as an independent risk factor for venous thromboembolism (VTE). However, it should be noted, that the risk of VTE is not consistent among all cytotoxic agents. In addition, different supportive care drugs, such as erythropoiesis stimulating agents or granulocyte colony stimulating factors, and hormonotherapy have been associated to an increased risk of VTE. Immunotherapy and molecular-targeted therapies have significantly changed the treatment of cancer over the past decade. The main subtypes include tyrosine-kinase inhibitors, monoclonal antibodies, small molecules, and immunomodulatory agents. The relationship between VTE and targeted therapies remains largely unknown.